Saturday, 31 October 2026European Markets

MAUNA KEA TECH Stock Bullish By 9% So Far On Thursday

Loading stream...

(vianews) - shares of mauna kea tech (cac 40: mkea.pa) rose 9.67% to €0.64 at 14:00 est on thursday, following the last session's downward trend. cac 40 is sliding 0.48% to €7,289.82, after two successive sessions in a row of losses. this seems, so far, a somewhat bearish trend trading session today.

mauna kea tech's last close was €0.58, 41.31% below its 52-week high of €0.99.

about mauna kea tech

mauna kea technologies sa develops and markets medical devices in europe, the middle east, africa, the united states, latin america, and asia. the company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. its flagship product is cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. the company was incorporated in 2000 and is headquartered in paris, france.

earnings per share

as for profitability, mauna kea tech has a trailing twelve months eps of €-0.418.

volatility

mauna kea tech's last week, last month's, and last quarter's current intraday variation average was a negative 0.11%, a negative 0.80%, and a positive 3.15%.

mauna kea tech's highest amplitude of average volatility was 2.44% (last week), 2.43% (last month), and 3.15% (last quarter).

volume

today's last reported volume for mauna kea tech is 694699 which is 102.78% above its average volume of 342584.

more news about mauna kea tech (mkea.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com